Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms

Chemistry and Biology

Volumn 11, Issue 6, 2004, Pages 775-785

  Wright, Lisa ^a   Barril, Xavier ^a   Dymock, Brian ^a   Sheridan, Louisa ^a   Surgenor, Allan ^a   Beswick, Mandy ^a   Drysdale, Martin ^a   Collier, Adam ^a   Massey, Andy ^a   Davies, Nick ^a   Fink, Alex ^a   Fromont, Christophe ^a   Aherne, Wynne ^b   Boxall, Kathy ^b   Sharp, Swee ^b   Workman, Paul ^b   Hubbard, Roderick E ^a  

^a Vernalis PLC   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

9 (N BUTYL) 8 ((3,4,5 TRIMETHOXYPHENYL)METHYL)ADENINE; 9-(N-BUTYL)-8-((3,4,5-TRIMETHOXYPHENYL)METHYL)ADENINE; ADENINE; ADENOSINE TRIPHOSPHATASE; ANISOLE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; HSP90BETA PROTEIN, HUMAN; ISOPROTEIN; LIGAND; PURINE DERIVATIVE;

ARTICLE; BINDING SITE; CELL DIVISION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ADENINE; ADENOSINE TRIPHOSPHATASES; ANISOLES; BINDING SITES; CELL DIVISION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042637928     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.03.033     Document Type: Article

References (32)

1. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy. the story unfolds Expert Opin. Biol. Ther. 2:2002;3-24
2. Isaacs J.S., Xu W., Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 3:2003;213-217
3. Pearl L.H., Prodromou C. Structure and in vivo function of HSP90. Curr. Opin. Struct. Biol. 10:2001;46-51
4. Marcu M.G., Chadli A., Bouhouche I., Catelli M., Neckers L.M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275:2000;37181-37186
5. Langer T., Schlatter H., Fasold H. Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (HSP90) is necessary for its autophosphorylation. Cell Biol. Int. 26:2002;653-657
6. Meyer P., Prodromou C., Hu B., Vaughan C., Roe S.M., Panaretou B., Piper P.W., Pearl L.H. Structural and functional analysis of the middle segment of hsp90. implications for ATP hydrolysis and client protein and cochaperone interactions Mol. Cell. 11:2003;647-658
7. Bergerat A., de Massy B., Gadelle D., Varoutas P.C., Nicolas A., Forterre P. An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature. 386:1997;329-331
8. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an HSP90-geldanamycin complex. targeting of a protein chaperone by an antitumor agent Cell. 89:1997;239-250
9. Dutta R., Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25:2000;24-28
10. Chiosis G., Timaul M.N., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8:2001;289-299
11. Chiosis G., Lucas B., Shtil A., Huezo H., Rosen N. Development of a purine-scaffold novel class of HSP90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10:2002;55-64
12. Dymock B., Barril X., Beswick M., Collier A., Davies N., Drysdale M., Fink A., Fromont C., Hubbard R.E., Massey A., et al. Adenine derived inhibitors of the molecular chaperone HSP90 - SAR explained through multiple Xray structures. Bioorg. Med. Chem. Lett. 14:2004;325-328
13. Obermann W.M., Sondermann H., Russo A.A., Pavletich N.P., Hartl F.U. In vivo function of HSP90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol. 143:1998;901-910
14. Roe S.M., Prodromou C., O'Brian R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the HSP90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266
15. Besant P.G., Lasker M.V., Bui C.D., Turck C.W. Inhibition of branched-chain alpha-keto acid dehydrogenase kinase and Sln1 yeast histidine kinase by the antifungal antibiotic radicicol. Mol. Pharmacol. 62:2002;289-296
16. Rowlands M.G., Newbatt Y.M., Prodromou C., Pearl L.H., Workman P., Aherne W. High throughput screening assay for inhibitors of heat-shock protein 90 (HSP90) ATPase activity. Anal. Biochem. 327:2004;176-183
17. Clarke P.A., Hostein I., Banerji U., Stefano F.D., Maloney A., Walton M., Judson I., Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17- demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene. 19:2000;4125-4133
18. Clark M., Cramer R.D. III, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J. Comput. Chem. 10:1989;982-1012
19. Orozco M., Luque F.J. Molecular interaction potential (MIP). A new tool for the theoretical study of molecular reactivity. J. Comput. Chem. 14:1993;587-602
20. Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology, Volume 276, Macromolecular Crystallography, Part A, C.W. Carter, Jr. and R.M. Sweet, eds. (Academic Press), pp. 307-326.
21. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D. 53:1997;240-255
22. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119
23. Lamzin V.S., Wilson K.S. Automated refinement of protein models. Acta Crystallogr. D. 49:1993;129-149
24. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. Procheck. a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26:1993;283-291
25. Navaza J. AMoRe. an automated package for molecular replacement Acta Crystallogr. 50:1994;157-163
26. CCP4 Collaborative Computational Project, Number 4) The CCP4 suite. programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50:1994;760-763
27. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112
28. Schmidt M.W., Baldridge K.K., Boatz J.A., Elbert S.T., Gordon M.S., Jensen J.H., Koseki S., Matsunaga N., Nguyen K.A., Su S., et al. General atomic and molecular electronic structure system. J. Comput. Chem. 14:1993;1347-1363
29. Jorgensen W.L., Tirado-Rives J. The OPLS (optimized potentials for liquid simulations) potential functions for proteins. Energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 110:1988;1657-1666
30. Mayer M., Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 38:1999;1784-1788
31. Dalvit C., Pevarello P., Tato M., Veronesi M., Vulpetti A., Sundstrom M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR. 18:2000;65-68
32. Wallace A.C., Laskowski R.A., Thornton J.M. Ligplot. A program to generate schematic diagrams of protein-ligand interactions Protein Eng. 8:1995;127-134